HRCM
CRL icon

Hawk Ridge Capital Management’s Charles River Laboratories CRL Stock Holding History

Hawk Ridge Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,900
Closed -$1.55M – 49
2022
Q3 		$1.55M Hold
7,900
– – 0.1% 47
2022
Q2 		$1.69M Buy
7,900
+4,300
+119% +$1.05M 0.12% 45
2022
Q1 		$1.02M Buy
+3,600
New +$1.11M 0.06% 50

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Hawk Ridge Capital Management's CRL Position: Q4 2022 in Review

Hawk Ridge Capital Management sold out of Charles River Laboratories (CRL) in Q4 2022, closing a stake of 7,900 shares — an estimated $1.55M sold.

Hawk Ridge Capital Management first reported a position in CRL in Q1 2022 and held it in 3 quarters. The position peaked at $1.69M in Q2 2022. 627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

  • Hawk Ridge Capital Management reported no remaining Charles River Laboratories position as of Q4 2022 after selling out during the quarter.
  • Hawk Ridge Capital Management sold 7,900 Charles River Laboratories shares in Q4 2022, an estimated $1.55M.
  • Hawk Ridge Capital Management first reported a position in Charles River Laboratories in Q1 2022 and held it in 3 quarters.
  • Hawk Ridge Capital Management's Charles River Laboratories position peaked at $1.69M in Q2 2022.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on Hawk Ridge Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.